PBYI News and Press, Puma Biotechnology Inc From 01/13/20

Company Overview Puma Biotechnology ( PBYI ) is a pharmaceutical company producing drugs used in cancer treatments. Their main product is Nerylinx, a compound used to treat breast cancer, specifically those that are HER-2 positive. The company has seen much volatility in terms of earning...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its Chief Executive Officer and President, Alan H. Auerbach, will be presenting at the 38 th Annual J.P. Morgan Healthcare Conference at 12:00 p.m. PST on Wednesday, January 15, 2020. Mr. Auerbach will be pr...

Puma Biotechnology  (NASDAQ: PBYI) used to be a pretty compelling investment for many biotech investors out there. Its only drug, Nerlynx (also known as neratinib), targets a significant portion of the breast cancer patient population and definitely has the potential to be a lucrative ...

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 12:00 p.m. PST on Wednesday, January 15, at the 38 th Annual J.P. Morgan Healthc...

Puma Biotechnology ( PBYI ) reported $53.5M in product revenue for the third quarter of 2019, which was a 0.6% decline from the $53.8M in Q2. I was expecting an evisceration of the share price and strong tax-selling event leaving 2019. Remarkably, the market eventually found some positive ...

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma’s drug neratinib at the 2019 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas. The presentat...

Sarepta Therapeutics (NASDAQ: SRPT )  +31%  on FDA nod for golodirsen. More news on: Sarepta Therapeutics, Inc., BioLineRx Ltd., The Royal Bank of Scotland Group plc, Stocks on the move, Read more ...

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that its collaborators at The Institute of Cancer Research, London, presented results from the cohort of patients in the plasmaMATCH trial treated with Puma's drug neratinib at the 2019 San Antonio Breast Cancer S...

Puma Biotechnology (NASDAQ: PBYI ) is up  5%  premarket on light volume in response to results from an ongoing open-label Phase 2 basket study, SUMMIT , evaluating Nerlynx (neratinib), combined with Roche's Herceptin (trastuzumab) and AstraZeneca's Faslodex (fulvestrant), in pat...

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's drug neratinib are being presented at the 2019 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas. The p...